Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8 Lymphoid 5 Genitourinary 4 Head & Neck 2 Dermatologic 2 Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 CNS 1 Breast 1

Conditions

All Solid Tumors 1

Interventions

Cisplatin 81 Gemcitabine 58 Carboplatin 57 Irinotecan 56 Paclitaxel 53 Pemetrexed 47 Docetaxel 39 Nivolumab 33 Fluorouracil 30 Bevacizumab 27 pembrolizumab 25 Cyclophosphamide 24 Capecitabine 24 Oxaliplatin 22 Leucovorin 21 Topotecan 19 durvalumab 17 Erlotinib Hydrochloride 17 Sorafenib 16 Everolimus 16 Etoposide 16 Bortezomib 16 Ipilimumab 15 Injections 15 Sunitinib 14 Filgrastim 14 Early Intervention, Educational 14 atezolizumab 13 alvocidib 13 Sirolimus 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Pharmaceutical Preparations × Other solid neoplasm × Clear all

NCT01711398 2015-02-12

IP N02

Elro Pharma

Phase 1/2 Completed

Other solid neoplasm

All Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡